YasushiUekiMD, PhDaTatsuhikoOtsukaMDaSarahBärMDaKostantinos C.KoskinasMD, MScaDikHegPhDbJonasHänerMDaGeorge C.M.SiontisMD, PhDaFabienPrazMDaLukasHunzikerMDaJonasLanzMD, MScaStefanStorteckyMD, MPHaThomasPilgrimMD, MScaSylvainLosdatPhDbStephanWindeckerMDaLorenzRäberMD, PhDa
doi : 10.1016/j.jacc.2021.11.047
Volume 79, Issue 6, 15 February 2022, Pages 513-526
Definitions of periprocedural myocardial infarction (MI) differ with respect to biomarker threshold as well as ancillary criteria for myocardial ischemia and are limited in terms of validation.
Cian P.McCarthyMB, BCh, BAOaJames L.JanuzziJr.MDab
doi : 10.1016/j.jacc.2021.11.046
Volume 79, Issue 6, 15 February 2022, Pages 527-529
AparnaSajjaMDabHsin-FangLiPhDcKateri J.SpinelliPhDcRoger S.BlumenthalMDbSalim S.ViraniMD, PhDdSeth S.MartinMD, MHSbTy J.GluckmanMD, MHAbc
doi : 10.1016/j.jacc.2021.11.042
Volume 79, Issue 6, 15 February 2022, Pages 530-541
Accurate estimation of low-density lipoprotein cholesterol (LDL-C) is important for guiding cholesterol-lowering therapy. Different methods currently exist to estimate LDL-C.
Kevin C.MakiPhDabJelani K.GrantMDcCarl E.OrringerMDc
doi : 10.1016/j.jacc.2021.12.005
Volume 79, Issue 6, 15 February 2022, Pages 542-544
MortenKaltoftMDabcAnneLangstedMD, PhDabcShoaibAfzalMD, PhD, DMScabcPia R.KamstrupMD, PhDabBørge G.NordestgaardMD, DMScabc
doi : 10.1016/j.jacc.2021.11.043
Volume 79, Issue 6, 15 February 2022, Pages 545-558
High plasma lipoprotein(a) and high body mass index are both causal risk factors for calcific aortic valve disease.
Nalini M.RajamannanMD
doi : 10.1016/j.jacc.2021.11.044
Volume 79, Issue 6, 15 February 2022, Pages 559-561
SergioRaposeiras-RoubinMD, PhDaMariannaAdamoMDbXavierFreixaMD, PhDcDabitArzamendiMD, PhDdTomasBenito-GonzálezMDeAntonioMontefuscoMD, PhDfIsaacPascualMD, PhDgLuisNombela-FrancoMD, PhDhJosepRodes-CabauMD, PhDiMonyShuvyMD, PhDjAntonioPortolés-HernándezMD, PhDkCosmoGodinoMD, PhDlBereniceCaneiro-QueijaMDaLauraLupiMDbAnderRegueiroMD, PhDcChin HionLiMD, PhDdFelipeFernández-VázquezMD, PhDeSimoneFreaMD, PhDf…RodrigoEstévez-LoureiroMD, PhDa
doi : 10.1016/j.jacc.2021.11.041
Volume 79, Issue 6, 15 February 2022, Pages 562-573
Risk stratification for transcatheter edge-to-edge mitral valve repair (TEER) is paramount in the decision-making process for treating severe mitral regurgitation (MR).
MohamadAlkhouliMDaIgor F.PalaciosMDbHaniJneidMDc
doi : 10.1016/j.jacc.2021.12.003
Volume 79, Issue 6, 15 February 2022, Pages 574-576
Jacqueline T.VuongMDaAshley F.Stein-MerlobMDbArashNayeriMDbTamerSallamMD, PHDbTomas G.NeilanMD, MPHcEric H.YangMDbd
doi : 10.1016/j.jacc.2021.11.048
Volume 79, Issue 6, 15 February 2022, Pages 577-593
Immune checkpoint inhibitor therapy has revolutionized the treatment of advanced malignancies in recent years. Numerous reports have detailed the myriad of possible adverse inflammatory effects of immune checkpoint therapies, including within the cardiovascular system. However, these reports have been largely limited to myocarditis. The critical role of inflammation and adaptive immunity in atherosclerosis has been well characterized in preclinical studies, and several emerging clinical studies indicate a potential role of immune checkpoint targeting therapies in the development and exacerbation of atherosclerosis. In this review, we provide an overview of the role of T-cell immunity in atherogenesis and describe the molecular effects and clinical associations of both approved and investigational immune checkpoint therapy on atherosclerosis. We also highlight the role of cholesterol metabolism in oncogenesis and discuss the implications of these associations on future treatment and monitoring of atherosclerotic cardiovascular disease in the oncologic population receiving immune checkpoint therapy.
KarimTahaMDab∗Feddo P.KirkelsMDabc∗Arco J.TeskeMD, PhDaFolkert W.AsselbergsMD, PhDadeJ. Petervan TintelenMD, PhDfPieter A.DoevendansMD, PhDabgShelbyKuttyMD, PhDhKristina H.HaugaaMD, PhDciMaarten J.CramerMD, PhDa
doi : 10.1016/j.jacc.2021.11.045
Volume 79, Issue 6, 15 February 2022, Pages 594-608
Clinical screening of the relatives of patients with genetic cardiomyopathies is challenging, as they often lack detectable cardiac abnormalities at presentation. Life-threatening adverse events can already occur in these early stages of disease, so sensitive tools to reveal the earliest signs of disease are needed. The utility of echocardiographic deformation imaging for early detection has been explored for this population in multiple studies but has not been broadly implemented in clinical practice. The authors discuss contemporary evidence on the utility of deformation imaging in relatives of patients with genetic cardiomyopathies. The available body of data shows that deformation imaging reveals early disease-specific abnormalities in dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic cardiomyopathy. Deformation imaging seems promising to enhance the screening and follow-up protocols in relatives, and the authors propose measures to accelerate its implementation in clinical care.
Connor G.O’BrienMDaChristopher F.BarnettMD, MPHaDavid M.DudzinskiMD, JDbPablo A.SanchezMDcJason N.KatzMD, MHSdJohn G.HaroldMDeErin K.HennesseyMDfPaul K.MohabirMDg
doi : 10.1016/j.jacc.2021.12.009
Volume 79, Issue 6, 15 February 2022, Pages 609-613
Author links open overlay panelKeerat RaiAhujaMDAnasQatananiBSAbdul MannanKhan MinhasMDRobert W.ArissBSAsifMahmoodMDSatish KumarAhujaMBBSRohitVyasMDSalikNazirMD
doi : 10.1016/j.jacc.2021.12.004
Volume 79, Issue 6, 15 February 2022, Pages 614-616
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟